Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2018-11-12 M&A Activity
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Arix Bioscience Plc - Arix invests in $70m Harpoon Series C investment round
M&A Activity Classification · 1% confidence The document is a press release announcing that Arix Bioscience plc invested $8.0 million in Harpoon Therapeutics' Series C financing round. This announcement details a specific financing activity, an increase in investment stake, and the valuation uplift resulting from the transaction. This clearly falls under the category of updates on company fundraising or capital structure changes, matching the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific corporate finance event.
2018-11-12 English
Arix Bioscience Plc - Autolus Therapeutics to Present New Data at the ASH
Regulatory Filings Classification · 1% confidence The document is a press release issued by Arix Bioscience plc, noting that its Group Business, Autolus Therapeutics, will present new data at the American Society of Hematology (ASH) Annual Meeting. It details the specific presentations (oral and poster) including titles, session names, dates, and locations. This type of announcement, detailing upcoming scientific presentations or data releases, is characteristic of investor relations communication, often preceding a formal earnings release or a dedicated investor presentation. Since it is an announcement about scientific data presentation at a conference, it fits best under Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the detailed nature of the scientific updates and the context of presenting data to investors/the scientific community, 'Investor Presentation' (IP) is the most appropriate fit, as it often encompasses such scientific updates, even if the actual presentation slides are not attached (it is an announcement *about* the presentation). It is not a full 10-K, AR, or IR. It is not a simple earnings release (ER) as it focuses on scientific data, not financial results. It is not a Report Publication Announcement (RPA) because it is announcing participation in a conference, not the publication of a formal company report like an Annual Report or Quarterly Report.
2018-11-02 English
Arix Bioscience Plc - Aura Biosciences reports positive Phase 1b/2 data
Legal Proceedings Report Classification · 1% confidence The document is a press release issued by Arix Bioscience plc, reporting on positive clinical data from Aura Biosciences regarding their drug candidate AU-011 for choroidal melanoma. It details clinical trial phases (Phase 1b/2), efficacy endpoints, safety profiles, and future plans (pivotal Phase 3 study initiation). This content strongly aligns with an Earnings Release (ER) which typically announces key financial or operational results, or an Investor Presentation (IP) if it were a slide deck, but as a press release detailing recent operational milestones (clinical data), it fits best under the general category of an Earnings Release or a related operational update. Since it is not a full quarterly/interim report (IR) or the official annual report (10-K), and it focuses on announcing key results, ER is the most appropriate fit among the options for a major operational/clinical update announcement. It is not a CTA, DVA, or DIRS filing. Given the nature of reporting clinical trial progress, it is a significant operational announcement, often released concurrently with or instead of a formal earnings report.
2018-10-30 English
Arix Bioscience Plc - LogicBio announces closing of initial public offering
Capital/Financing Update Classification · 1% confidence The document is a press release from Arix Bioscience plc announcing the closing of the Initial Public Offering (IPO) of one of its group businesses, LogicBio Therapeutics, Inc. This announcement details the share price, gross proceeds, Arix's retained stake, and the resulting gain on investment. An IPO closing announcement, especially one detailing financing outcomes and share structure changes, falls under the category of Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it specifically concerns a capital raising event.
2018-10-24 English
Arix Bioscience Plc - LogicBio prices Nasdaq IPO
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing that LogicBio, a company in which Arix Bioscience plc has a stake, has priced its Initial Public Offering (IPO) on Nasdaq. This announcement details financing activities, investment retention, and the resulting valuation changes for Arix. This clearly falls under the category of updates on company fundraising, financing activities, or capital structure changes, which corresponds to the 'Capital/Financing Update' definition.
2018-10-19 English
Arix Bioscience Plc - Update on LogicBio proposed IPO in the United States
Capital/Financing Update Classification · 1% confidence The document is a press release from Arix Bioscience plc announcing that its portfolio company, LogicBio Therapeutics Inc., has filed an amended registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering (IPO) in the United States. This filing relates directly to a proposed merger, takeover, or significant transaction involving the company's assets or subsidiaries, specifically an IPO of a major holding. This aligns best with the 'M&A Activity' category (TAR), which covers merger proposals or takeover bids, as an IPO of a significant stake often falls under strategic transaction reporting. Although it is an announcement, the subject matter is a specific, major corporate transaction (IPO), making TAR more precise than the general RPA or RNS.
2018-10-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.